Publications by authors named "Scott Andersen"

Claim this Profile
D
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Jennifer A Zimmer, John R Sims, Cynthia D Evans, Emel Serap Monkul Nery, Hong Wang, Scott W Andersen

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Scott W Andersen

J Prev Alzheimers Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans, Scott Andersen

JAMA Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Scott W Andersen

Alzheimers Dement· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, Scott W Andersen

JAMA Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
Adam S Fleisher, Leanne M Munsie, David G S Perahia, Scott W Andersen, Ixavier A Higgins

Neurology· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The maps of meaning consciousness theory.
Scott Andersen

Front Psychol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Cynthia D Evans, JonDavid Sparks, Scott W Andersen, Dawn A Brooks, Paula M Hauck

Alzheimers Dement· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.
Karen C Holdridge, Roy Yaari, Deirdre B Hoban, Scott Andersen, John R Sims

Alzheimers Dement· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
Brian A Willis, Albert C Lo, Jeffrey L Dage, Sergey Shcherbinin, Louise Chinchen, Scott W Andersen

J Alzheimers Dis Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Sergey Shcherbinin, Cynthia D Evans, Ming Lu, Scott W Andersen, Michael J Pontecorvo

JAMA Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway, Martin Farlow, Eric McDade, David B Clifford, Guoqiao Wang, Scott W Andersen

Nat Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in Early Alzheimer's Disease.
Mark A Mintun, Albert C Lo, Cynthia Duggan Evans, Alette M Wessels, Paul A Ardayfio, Scott W Andersen

N Engl J Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Jennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, Sonja M Bragg, Katherine J Selzler, Scott W Andersen

Alzheimers Dement (N Y)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
Alette M Wessels, Christopher Lines, Robert A Stern, James Kost, Tiffini Voss, Scott W Andersen

Alzheimers Dement· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.
Scott A Monk, Alan R Kugler, Scott W Andersen, Mosun A Ayan-Oshodi, Douglas E James

J Clin Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Modification in Alzheimer's Disease: Current Thinking.
Hong Liu-Seifert, Jennifer Schumi, Xiaopeng Miao, Ying Tian, Michael Rabbia, Scott W Andersen

Ther Innov Regul Sci· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Alette M Wessels, Pierre N Tariot, Jennifer A Zimmer, Katherine J Selzler, Sonja M Bragg, Scott W Andersen

JAMA Neurol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Brian A Willis, Scott W Andersen, Mosun Ayan-Oshodi, Douglas E James, Emily Liffick

J Clin Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation of cutoffs for the Elecsys amyloid β (1-42) assay in Alzheimer's disease.
Leslie M Shaw, Teresa Waligorska, Leona Fields, Magdalena Korecka, Michal Figurski, Scott W Andersen

Alzheimers Dement (Amst)· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical properties of continuous composite scales and implications for drug development.
Hong Liu-Seifert, Scott Andersen, Michael Case, JonDavid Sparks, Karen C Holdridge

J Biopharm Stat· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease.
Hong Liu-Seifert, Scott W Andersen, Ilya Lipkovich, Karen C Holdridge, Eric Siemers

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.
Hong Liu-Seifert, Eric Siemers, Karen C Holdridge, Scott W Andersen, Ilya Lipkovich

Alzheimers Dement (N Y)· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur

Schizophr Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the practical application of mixed effects models for repeated measures to clinical trial data.
Scott W Andersen, Brian A Millen

Pharm Stat· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis